What’s on Sanofi’s M&A list now that Medivation is gone? Catalyst gets an SPA; Adaptimmune partners with Merck
As we’ve said before at Endpoints News, this has been a rough year for Sanofi $SNY. Now that Medivation has slipped through its fingers, falling to Pfizer, CEO Olivier Brandicourt has had to answer fresh questions about its M&A strategy. What will be their next target? The answer — in their Q3 call — was cancer, immunology and rare diseases. Says the CEO: “When it comes to what is going to be our interest in the future, oncology is still part of it, if we are finding potential targets which make sense strategically and economically. But we are opening our M&A strategy to what we said last year, which is a segment where we consider that we have established, already, some good presence, but we need to strengthen that presence by inorganic growth. And so, we mentioned several things last year. We mentioned immunology, we mentioned MS. Even in the first market, if you think about it, we are in genetic rare diseases, so rare disease can be also an area.”
Catalyst Pharmaceuticals says it has reached an agreement with the FDA on an SPA for the late-stage study of Firdapse (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome.